Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Its news flow reflects both scientific progress and corporate developments, making the MRSN news page a focused source for investors and observers following oncology drug development and transaction activity.
Company press releases emphasize updates from its ADC pipeline, particularly Emi-Le (emiltatug ledadotin; XMT-1660), a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope. News items have covered interim Phase 1 clinical data for Emi-Le in triple-negative breast cancer and adenoid cystic carcinoma type 1, including objective response rates and safety observations, as well as plans for dose expansion cohorts and future data readouts. Additional scientific news includes presentations at major oncology congresses such as ASCO and ESMO Breast Cancer.
Mersana’s news releases also detail collaboration milestones with partners including GSK, Janssen Biotech, Inc. (Johnson & Johnson) and Merck KGaA, Darmstadt, Germany. Examples include the achievement of development milestone payments and FDA clearance of an investigational new drug application for a Dolasynthen ADC developed under a collaboration. Corporate and capital markets news has included announcements of quarterly financial results, a 1-for-25 reverse stock split designed to support Nasdaq listing compliance, and notices related to Nasdaq listing standards.
A significant portion of recent news is devoted to the proposed acquisition of Mersana by Day One Biopharmaceuticals, Inc., including the terms of the tender offer, the structure of the contingent value rights and the expected timing of closing. Readers of the MRSN news page can therefore expect a mix of clinical trial updates, collaboration developments, financial disclosures, listing-related actions and transaction announcements. For ongoing context around these events, this page can be revisited as new company communications are released.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) will participate in a fireside chat on February 24, 2021, at 10:00 a.m. ET, during the SVB Leerink 10th Annual Global Healthcare Conference. Investors can access a live webcast on the company’s website, with an archived replay available for 90 days post-event. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with lead candidate upifitamab rilsodotin (XMT-1536) in clinical studies for ovarian cancer and NSCLC. The company also has several promising ADCs in its pipeline targeting specific tumor types.
Mersana Therapeutics (Nasdaq: MRSN) announced an inducement award for its new Senior VP and Chief Human Resources Officer, Carla Poulson. The Board of Directors approved a stock option grant allowing Ms. Poulson to purchase 100,000 shares at $21.67 each. The shares will vest over four years, with 25% vesting after the first year and the remainder in quarterly installments. Mersana specializes in antibody-drug conjugates (ADCs) aimed at treating cancers, with ongoing clinical studies for its lead product candidates.
Mersana Therapeutics, Inc. (Nasdaq: MRSN) announced the appointment of Carla Poulson as Chief Human Resources Officer on January 19, 2021. Poulson brings extensive experience in organizational development from her previous roles at Akcea Therapeutics and Vertex Pharmaceuticals. The leadership team is optimistic about her impact on the company, especially as it scales its operations to support its promising pipeline of antibody-drug conjugates targeting high unmet medical needs. Mersana is advancing clinical studies for its leading candidates, XMT-1536 and XMT-1592.
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced that President and CEO Anna Protopapas will present a company overview at the 39th Annual J.P. Morgan Conference on January 13, 2021, at 5:20 p.m. ET. The event will be held virtually, and a live webcast will be accessible on Mersana’s website, with an archived replay available for 90 days. Mersana focuses on developing antibody-drug conjugates (ADCs) aimed at treating cancers with high unmet medical needs, with notable candidates XMT-1536 and XMT-1592 currently in clinical studies.
Mersana Therapeutics (NASDAQ:MRSN) announced plans for the UPLIFT single-arm registration study for XMT-1536 in platinum-resistant ovarian cancer, following FDA feedback. The company reported consistent activity and tolerability in its Phase 1 study, with encouraging response rates observed. Mersana ended Q4 2020 with approximately $255 million in cash, ensuring operational stability for the next two years and beyond. Additional studies for XMT-1660, an ADC targeting B7-H4, are expected to complete IND-enabling studies by Q4 2021.
Mersana Therapeutics (NASDAQ:MRSN) will host a virtual Analyst and Investor event on January 5, 2021, from 10:00 a.m. to 12:00 p.m. ET. The event will feature key updates on XMT-1536, Mersana's first-in-class ADC candidate for ovarian cancer. Dr. Debra L. Richardson will present data from ongoing studies, while the management team will outline plans for registration-enabling studies and reveal preclinical data for the B7-H4 DolaLock ADC. Additionally, 2021 goals and milestones for clinical programs will be discussed. A live webcast will be available on Mersana's website.
On December 2, 2020, Mersana Therapeutics (MRSN) announced the appointment of Arvin Yang, M.D., Ph.D. as the Senior Vice President and Chief Medical Officer. The Compensation Committee approved an inducement stock option grant allowing Dr. Yang to purchase up to 200,000 shares at $25.48 each, with a four-year vesting schedule. Mersana is focused on antibody-drug conjugates (ADCs) for cancer treatment, with notable candidates XMT-1536 and XMT-1592 currently in clinical studies.
Mersana Therapeutics (Nasdaq: MRSN) announced the appointment of Arvin Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer, effective immediately. Dr. Yang succeeds Dirk Huebner, M.D., who will assist in the transition until January 15, 2021. With over a decade of experience at Bristol Myers Squibb, Dr. Yang's background in global registration trials and oncology is expected to accelerate the advancement of Mersana’s lead candidate, XMT-1536, in ovarian cancer. The company aims to leverage his expertise to drive its innovative pipeline.
Mersana Therapeutics (NASDAQ:MRSN) announced preclinical data on its Immunosynthen STING-Agonist ADC platform, showcased during the SITC Annual Meeting from November 9-14, 2020. This innovative approach activates the STING pathway in both tumor and immune cells, enhancing anti-tumor efficacy. The findings suggest that ADCs can potentially deliver a superior therapeutic effect compared to traditional immune activators. Mersana's pipeline includes ADCs like XMT-1536, currently in Phase 1 studies for ovarian cancer, and XMT-1592 targeting NaPi2b-expressing tumors.
Mersana Therapeutics (NASDAQ:MRSN) announced a live webinar on November 16, 2020, at 8:00 a.m. ET to showcase its Immunosynthen STING-agonist ADC platform. The session will include discussions on preclinical data demonstrating STING activation in tumor and immune cells, the optimization of the platform, and the timeline for the first investigational drug candidate. The event can be accessed via their website or through a dedicated phone line.
Mersana is committed to developing antibody-drug conjugates (ADCs) to improve cancer treatment options.
FAQ
What is the current stock price of Mersana Therapeutics (MRSN)?
What is the market cap of Mersana Therapeutics (MRSN)?
